Skip Navigation

European Heart Journal 2004 25(9):716-719; doi:10.1016/j.ehj.2003.12.024
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Watts, G. F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Watts, G. F
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Treating low HDL-cholesterol in normocholesterolaemic patients with coronary disease: statins, fibrates or horses for courses?

Gerald F Watts*

University of Western Australia, School of Medicine and Pharmacology, Royal Perth Hospital Unit, GPO Box X2213, Perth WA 6847, Australia

* Correspondence to: Fax: +61-8-9224-0246
E-mail address: gfwatts@cyllene.uwa.edu.au

The first 150 words of the full text of this article appear below.

This editorial refers to "Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study"1 by D. Colquhoun et al. on page 771.

A low plasma concentration of high-density lipoprotein (HDL)-cholesterol is a powerful independent risk factor for coronary heart disease (CHD). This notion is supported by consistent evidence from epidemiological, clinical and experimental studies.1 Low plasma HDL-cholesterol is frequently encountered in patients with CHD, either as part of the `atherogenic-lipid-triad' seen in central obesity or type 2 diabetes,2 or as an isolated lipoprotein abnormality of genetic origin. At present, the expert recommendation is that CHD patients who have appropriately modified their lifestyle and who have an optimal low-density lipoprotein (LDL)-cholesterol (2.6 mmol/L) and low HDL-cholesterol (1.05 mmol/L) be treated with HDL modifying pharmacotherapy, such as a fibrate or nicotinic acid.3 In . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study
David Colquhoun, Anthony Keech, David Hunt, Ian Marschner, John Simes, Paul Glasziou, Harvey White, Philip Barter, Andrew Tonkin, and for the LIPID Study Investigators
EHJ 2004 25: 771-777. [Abstract] [FREE Full Text]